Definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced cervical esophageal cancer

Abstract

Background

Recently, definitive chemoradiotherapy (dCRT) has become one of the essential treatment strategies for esophageal squamous cell carcinoma (ESCC) and has been especially gaining prevalence for cervical ESCC to preserve the larynx. Our department recently introduced dCRT concomitant with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for treating advanced cervical ESCC. This study aims to assess the safety and outcomes of DCF-R in patients with advanced cervical ESCC.

Methods

We retrospectively assessed 11 patients with advanced cervical ESCC (clinical stage: II–IV, including T4b and/or M1 lymph node) who received DCF-R as the first-line treatment between December 2010 and February 2015.

Results

Our patient cohort comprised 8 males and 3 females (median age 68 years; range 54–76 years). The pretreatment clinical stage included stage II (1), stage III (7), and stage IV (3) cases [including 3 patients with T4b (2 trachea and 1 thyroid) and 3 patients with M1 lymph node]. We attained complete response (CR) in 10 patients and stable disease in 1 patient. Of 10 patients with CR, 5 experienced recurrence and 5 continued exhibiting CR. Furthermore, grade 3 or more adverse events included leucopenia (91%), neutropenia (91%), febrile neutropenia (45%), and pharyngeal pain (55%). While the 2-year overall survival rate was 72%, the 2-year recurrent-free survival rate was 64%, respectively.

Conclusions

DCF-R treatment for advanced cervical esophageal cancer could be completed by the careful administration; although a strong blood toxicity might occur, this treatment may provide the chance to obtain favorable prognosis with larynx preservation.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2

References

  1. 1.

    Kato K, Muro K, Minashi K, et al. Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II–III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906). Int J Radiat Oncol Biol Phys. 2011;81:684–90.

    CAS  Article  PubMed  Google Scholar 

  2. 2.

    Ariga H, Nemoto K, Miyazaki S, et al. Prospective comparison of surgery alone and chemoradiotherapy with selective surgery in resectable squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys. 2009;75:348–56.

    Article  PubMed  Google Scholar 

  3. 3.

    Higuchi K, Komori S, Tanabe S, et al. Definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer: a phase 2 trial (KDOG 0501-P2). Int J Radiat Oncol Biol Phys. 2014;89:872–9.

    CAS  Article  PubMed  Google Scholar 

  4. 4.

    Burmeister BH, Dickie G, Smithers BM, et al. Thirty-four patients with carcinoma of the cervical esophagus treated with chemoradiation therapy. Arch Otolaryngol Head Neck Surg. 2000;126:205–8.

    CAS  Article  PubMed  Google Scholar 

  5. 5.

    Cao C, Luo J, Gao L, et al. Definitive radiotherapy for cervical esophageal cancer. Head Neck. 2015;37:151–5.

    Article  PubMed  Google Scholar 

  6. 6.

    Gkika E, Gauler T, Eberhardt W, et al. Long-term results of definitive radiochemotherapy in locally advanced cancers of the cervical esophagus. Dis Esophagus. 2014;27:678–84.

    CAS  Article  PubMed  Google Scholar 

  7. 7.

    Kumabe A, Zenda S, Motegi A, et al. Long-term clinical results of concurrent chemoradiotherapy for patients with cervical esophageal squamous cell carcinoma. Anticancer Res. 2017;37:5039–44.

    PubMed  Google Scholar 

  8. 8.

    Li HX, Liu J, Cheng Y, et al. Concurrent chemoradiotherapy for cervical esophageal squamous cell carcinoma: treatment results from a prospective observational study. Dis Esophagus. 2018. https://doi.org/10.1093/dote/dox144

    Article  PubMed  Google Scholar 

  9. 9.

    Uno T, Isobe K, Kawakami H, et al. Concurrent chemoradiation for patients with squamous cell carcinoma of the cervical esophagus. Dis Esophagus. 2007;20:12–8.

    CAS  Article  PubMed  Google Scholar 

  10. 10.

    Yamada K, Murakami M, Okamoto Y, et al. Treatment results of radiotherapy for carcinoma of the cervical esophagus. Acta Oncol. 2006;45:1120–5.

    Article  PubMed  Google Scholar 

  11. 11.

    Zenda S, Kojima T, Kato K, et al. Multicenter phase 2 study of cisplatin and 5-fluorouracil with concurrent radiation therapy as an organ preservation approach in patients with squamous cell carcinoma of the cervical esophagus. Int J Radiat Oncol Biol Phys. 2016;96:976–84.

    CAS  Article  PubMed  Google Scholar 

  12. 12.

    Zhang P, Xi M, Zhao L, et al. Clinical efficacy and failure pattern in patients with cervical esophageal cancer treated with definitive chemoradiotherapy. Radiother Oncol. 2015;116:257–61.

    Article  PubMed  Google Scholar 

  13. 13.

    Ito M, Kodaira T, Tachibana H, et al. Clinical results of definitive chemoradiotherapy for cervical esophageal cancer: Comparison of failure pattern and toxicities between intensity-modulated radiotherapy and 3-dimensional conformal radiotherapy. Head Neck. 2017;39:2406–15.

    Article  PubMed  Google Scholar 

  14. 14.

    Daiko H, Hayashi R, Saikawa M, et al. Surgical management of carcinoma of the cervical esophagus. J Surg Oncol. 2007;96:166–72.

    Article  PubMed  Google Scholar 

  15. 15.

    Jiang M, He X, Wu D, et al. Reconstruction techniques for hypopharyngeal and cervical esophageal carcinoma. J Thorac Dis. 2015;7:449–54.

    PubMed Central  PubMed  Google Scholar 

  16. 16.

    Nishimaki T, Kanda T, Nakagawa S, et al. Outcomes and prognostic factors after surgical resection of hypopharyngeal and cervical esophageal carcinomas. Int Surg. 2002;87:38–44.

    PubMed  Google Scholar 

  17. 17.

    Triboulet JP, Mariette C, Chevalier D, et al. Surgical management of carcinoma of the hypopharynx and cervical esophagus: analysis of 209 cases. Arch Surg. 2001;136:1164–70.

    CAS  Article  PubMed  Google Scholar 

  18. 18.

    Wang HW, Chu PY, Kuo KT, et al. A reappraisal of surgical management for squamous cell carcinoma in the pharyngoesophageal junction. J Surg Oncol. 2006;93:468–76.

    Article  PubMed  Google Scholar 

  19. 19.

    Miyazaki T, Sohda M, Tanaka N, et al. Phase I/II study of docetaxel, cisplatin, and 5-fluorouracil combination chemoradiotherapy in patients with advanced esophageal cancer. Cancer Chemother Pharmacol. 2015;75:449–55.

    CAS  Article  PubMed  Google Scholar 

  20. 20.

    Fujishima F, Taniyama Y, Nakamura Y, et al. Residual carcinoma cells after chemoradiotherapy for esophageal squamous cell carcinoma patients: striving toward appropriate judgment of biopsy. Dis Esophagus. 2018;Epub ahead of print.

  21. 21.

    Cao CN, Luo JW, Gao L, et al. Intensity-modulated radiotherapy for cervical esophageal squamous cell carcinoma: clinical outcomes and patterns of failure. Eur Arch Otorhinolaryngol. 2016;273:741–7.

    Article  PubMed  Google Scholar 

  22. 22.

    Yang H, Feng C, Cai BN, et al. Comparison of three-dimensional conformal radiation therapy, intensity-modulated radiation therapy, and volumetric-modulated arc therapy in the treatment of cervical esophageal carcinoma. Dis Esophagus. 2017;30:1–8.

    PubMed  Google Scholar 

  23. 23.

    Zhao L, Zhou Y, Mu Y, et al. Patterns of failure and clinical outcomes of definitive radiotherapy for cervical esophageal cancer. Oncotarget. 2017;8:21852–60.

    PubMed Central  PubMed  Google Scholar 

  24. 24.

    Fenkell L, Kaminsky I, Breen S, et al. Dosimetric comparison of IMRT vs. 3D conformal radiotherapy in the treatment of cancer of the cervical esophagus. Radiother Oncol. 2008;89:287–91.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors thank Enago (http://www.enago.jp) for the English language review.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Hiroshi Okamoto.

Ethics declarations

Ethical statement

This study was approved by the ethical committee of our institute (accession number: 2017-4-064), and we obtained informed consent from all patients before enrollment. We conducted this study in accordance with the Declaration of Helsinki (1975).

Conflict of interest

The authors have no conflicts of interest or financial ties to disclose.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Okamoto, H., Taniyama, Y., Sakurai, T. et al. Definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced cervical esophageal cancer. Esophagus 15, 281–285 (2018). https://doi.org/10.1007/s10388-018-0627-7

Download citation

Keywords

  • Esophageal squamous cell carcinoma
  • Chemoradiotherapy
  • Docetaxel
  • Cisplatin
  • 5-Fluorouracil